BWX Technologies, Inc. (BWXT): A Bull Case Theory 

We came across a bullish thesis on BWX Technologies, Inc. on X.com by @TheValueist. In this article, we will summarize the bulls’ thesis on BWXT. BWX Technologies, Inc.’s share was trading at $173.20 as of December 16th. BWXT’s trailing and forward P/E were 51.86 and 41.32 respectively according to Yahoo Finance.

BWX Technologies, Inc. manufactures and sells nuclear components in the United States, Canada, and internationally. BWXT is a high-quality, strategically critical nuclear franchise with exceptional long-term demand visibility anchored by its Navy propulsion and NNSA businesses, which provide durable earnings, high barriers to entry, and strong cash flow support.

Around this core, management has successfully expanded into commercial nuclear components, advanced fuels, microreactors, and medical isotopes, delivering strong execution through 2025 with double-digit earnings growth, record backlog, rising guidance, and accelerating Commercial Operations performance following the Kinectrics acquisition.

Government Operations remain the economic backbone, supported by long-dated Navy pricing agreements, stable submarine and carrier demand, and expanding Special Materials programs tied to defense fuels and high-purity depleted uranium, while Technical Services adds diversified, cost-plus growth through DOE and NNSA site management. Commercial Operations have emerged as a meaningful growth engine, driven primarily by CANDU life-extension work, early SMR component content, and fast-growing medical isotopes, with margin expansion underway as mix improves. Despite these strengths, the equity valuation remains demanding.

Even after a pullback to roughly $175–$180 per share, BWXT trades at multiples that implicitly assume sustained mid-teens non-Navy revenue growth for more than a decade and commercial nuclear revenues exceeding $10 billion by 2040, requiring a scale and pace of global nuclear build-out well above historical norms.

Free cash flow generation is solid but constrained in the near term by working capital and customer-funded capex tied to growth programs, while longer-term inflection remains several years away. As a result, the investment debate centers less on business quality and more on whether the nuclear renaissance unfolds fast enough to justify what is already priced in. BWXT offers best-in-class strategic positioning and execution, but upside depends on accelerated commercial nuclear deployment, successful medical isotope expansion, and continued flawless delivery across complex, long-cycle programs.

Previously we covered a bullish thesis on Northrop Grumman Corporation (NOC) by Daan Rijnberk in March 2025, which highlighted its dominant defense platforms, expanding backlog, margin recovery, and shareholder-focused capital returns. The company’s stock price has appreciated approximately by 15.89% since our coverage. This is because execution remained solid amid rising defense demand. The thesis still stands as long-cycle military spending persists. @TheValueist shares a similar but emphasizes valuation risk.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.